FibroGen
Ashley Lasher has extensive experience in clinical supplies management, currently serving as Associate Director at FibroGen, Inc. since November 2020, where responsibilities include end-to-end clinical supplies management. Prior to this, Ashley held multiple roles at Exelixis, including Senior Clinical Supplies Manager, and gained significant experience at Gilead Sciences as a Planner in Clinical Supply Chain Management. Educational credentials include certificates in Clinical Research Conduct and Management from the University of California, Berkeley, and a B.A. in International Relations from the University of California, Davis. Previous roles also include positions in vehicle inspection and customer service.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.